MED12L and Familial prostate cancer: This result builds upon the findings of Taylor et al. who observed that amplifications of the Wnt/β-catenin pathway modulators MED12 and MED12L were also more common among BRCA2 PSV carriers and that BRCA2d prostate cancers have been shown to experience global hypomethylation relative to sporadic cancers7.